NovoCure Limited (NVCR)

NovoCure Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-136.23	-168.63	-207.04	-92.53	-58.35
Depreciation & Amortization	14.65	11.24	10.97	10.62	10.25
Stock-Based Compensation	104.83	160.04	115.61	106.96	94.9
Other Adjustments	-12.21	-25.36	-22.53	-6.05	6.89
Change in Receivables	-38.94	-26.36	29.41	2.55	5.27
Changes in Inventories	-5.67	2.57	-8.92	-4.34	2.48
Changes in Accrued Expenses	18.96	19.11	14.87	14.26	27.78
Changes in Other Operating Activities	5.57	1.04	-5.71	-0.67	-6.46
Operating Cash Flow	-49.03	-26.37	-73.34	30.79	82.76
Operating Cash Flow Growth	-	-	-	-62.80%	-
Capital Expenditures	-26.65	-42.86	-27.09	-21.36	-24.17
Purchases of Investments	-821.08	-875.39	-1,004	-1,298	-1,079
Proceeds from Sale of Investments	1,285	778	1,215	1,179	958
Investing Cash Flow	437.28	-140.24	184.15	-139.96	-144.83
Long-Term Debt Issued	99.98	96.92	-	-	-
Long-Term Debt Repaid	-560.95	-12.91	-0.01	-0.03	-0.03
Net Long-Term Debt Issued (Repaid)	-460.97	84.01	-0.01	-0.03	-0.03
Issuance of Common Stock	9.77	6.31	15.8	15.52	25.73
Net Common Stock Issued (Repurchased)	9.77	6.31	15.8	15.52	25.73
Other Financing Activities	-0.15	-	-	-	-
Financing Cash Flow	-451.34	90.32	15.79	15.49	25.7
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.39	-0.17	0.13	-0.1	-0.19
Net Cash Flow	-62.7	-76.47	126.73	-93.78	-36.56
Free Cash Flow	-75.68	-69.22	-100.43	9.43	58.59
Free Cash Flow Growth	-	-	-	-83.90%	-
FCF Margin	-11.55%	-11.44%	-19.72%	-	10.95%
Free Cash Flow Per Share	-0.68	-0.64	-0.94	0.09	0.56
Levered Free Cash Flow	-590.33	-93.53	-222.94	-1.51	-48.5
Unlevered Free Cash Flow	-146.96	-130.71	-230.17	-1.49	-29.11

Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q